Open — FY2026-27 application materials and intake postedAtlas Opportunity Score 91/100
Florida FY2026-27 BRAC Biomedical Research Grants
Florida's FY2026-27 Biomedical Research Advisory Council FOA funds cancer, pediatric-cancer, and tobacco-related biomedical research through the Bankhead-Coley, James and Esther King, and Live Like Bella programs. The required Letter of Intent closed September 2, 2026 at noon ET; the application stage is now open only to applicants with a timely LOI, with full applications due October 21, 2026 at noon ET.
FundingMechanism-specific: up to $1.5 million for Bankhead-Coley/James and Esther King clinical-trial/socio-behavioral interventions and research infrastructure; other mechanisms have lower caps. Live Like Bella multicenter clinical trials are capped at $900,000.
DeadlineSeptember 2, 2026 at 12:00 PM ET (required LOI); October 21, 2026 at 12:00 PM ET (full application)
Last verifiedOctober 7, 2026
Required next actionOnly applicants that submitted the required Letter of Intent by September 2, 2026 at noon ET remain eligible for this cycle. Those applicants should complete the appropriate BRAC application in PeerNet, confirm the selected program and grant mechanism, finalize the required work plan, evaluation plan, budget and supporting materials, and submit by October 21, 2026 at noon ET.
Broad Eligibility
Qualifying Florida-based universities, research hospitals, Florida-based Veterans Administration hospitals, and established research institutes. Established research institutes must be Florida-based nonprofit organizations in active Chapter 617 status with a physical Florida location and a stated scientific, biomedical, or biotechnological research/development purpose. Each proposal must identify an eligible PI and satisfy all FOA requirements.
Atlas Analysis
Florida Department of Health has current FY2026-27 biomedical-research materials posted for the Bankhead-Coley, James and Esther King, and Live Like Bella programs, including program-specific funding announcements, addenda, and application intake. Eligible Florida research organizations should use the controlling FY2026-27 materials for the selected mechanism and treat award ceilings, project terms, equipment, subcontract, and other budget categories as mechanism-specific rather than assuming they apply across every program.
Florida FY2026-27 Biomedical Research Advisory Council Grants
Application stage open only to applicants that submitted the required Letter of Intent by September 2, 2026 at 12:00 PM ET. The Florida Department of Health’s FY2026-27 BRAC Funding Opportunity Announcement covers the William G. “Bill” Bankhead Jr. and David Coley Cancer Research Program, the James and Esther King Biomedical Research Program, and the Live Like Bella Pediatric Cancer Research Initiative.
At a glance
- Required LOI: September 2, 2026 at 12:00 PM ET.
- Full application: October 21, 2026 at 12:00 PM ET.
- Maximum award: varies by mechanism; up to $1.5 million for Bankhead-Coley/King clinical-trial or socio-behavioral interventions and research infrastructure, with lower ceilings for other mechanisms. Bella Initiative mechanisms reach up to $900,000 for multicenter clinical trials.
- Eligible institutions: qualifying Florida-based universities, research hospitals, Florida-based VA hospitals, and established Florida research institutes meeting the FOA requirements.
- Research focus: cancer, pediatric cancer, and James and Esther King Program research addressing tobacco-related cancer, cardiovascular disease, stroke, and pulmonary disease.
- Atlas Opportunity Score: 91/100.
Important addendum
Addendum I supersedes the original schedule. Applications without a required LOI received by the September 2 deadline are not eligible and will not be considered. The application is anticipated to open September 8.
Funding and technology relevance
The FOA includes clinical research, emerging therapeutics and technologies, research infrastructure, and equipment mechanisms. Equipment must be essential to the research objectives and justified in the budget; the FOA expressly recognizes advanced imaging or diagnostic equipment and significant equipment upgrades. Subcontracts are allowed when justified and pre-approved.
Dr. Miltie / N9+ perspective
This is not a direct procurement for Dr. Miltie. N9+ could be considered only when a qualifying Florida investigator-led project has a defensible research need for connected diagnostic data capture, decentralized clinical-study workflows, or other research technology and the applicant can justify the cost under the controlling FOA. Atlas therefore does not classify this as a high-fit direct-vendor opportunity.
Required next action
Applicants that submitted the required LOI by September 2, 2026 at noon ET should now select the appropriate BRAC program and grant mechanism, validate PI and institutional eligibility, and build the full application to the amended October 21 noon ET deadline.
Source verificationOfficial government source · www.floridahealth.govAtlas last verified this record October 7, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
